Colloid Volume Kinetics in Morbidly Obese Patients Under General Anaesthesia
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- description of colloid volume kinetics in obese patients after the infusion of Tetrastarch (130/0.4)
Study Overview
Brief Summary
There is no objective evidence of how long intravenous solutions remain inside venous blood vessels after they have been administered, therefore there is no definite guideline of how to administer them in the preoperative setting. Besides, obese patients represent a particular group of subjects as they theoretically with-hold a constant inflammatory response and that would modify the way solutions behave intravenously, that is how long they remain inside.
Having said this, we wish to describe the way colloid solutions behave in this group of patients by taking serial blood samples in 12 obese patients after a colloid infusion, to calculate plasma dilution curves based on hemoglobin dilution and therefore infer the time it remains intravascularly.
All this in the hope this information will help, in the near future, to establish a more objective way to use these solutions and avoid possible complications due to over-administration.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •clinical diagnosis of obesity (IMC >35kg/m2) that will be treated with gastrojejunal laparoscopic bypass
Exclusion Criteria
- •Renal failure KDOQI >3
- •Cardiac failure NYHA III-IV
- •Allergy to tetrastarch
- •Allergy to any of the anesthetic medication that is to be used in the protocol previously established
- •Patients in which vasoactive drugs are used
- •Patients in which the blood samples are completed.
Outcomes
Primary Outcomes
description of colloid volume kinetics in obese patients after the infusion of Tetrastarch (130/0.4)
Time Frame: 90 minutes after beginning of the infusion
different kinetic parameters will be used to asses the behavior of the colloid solution
Secondary Outcomes
No secondary outcomes reported
Investigators
Maria Victoria Hernandez Martinez
M.D.
National Institute of Medical Sciences and Nutrition, Salvador Zubiran